Other News To Note
• Atlab Pharma SAS, of Nantes, France, and BZL Biologics LLC, of New York, entered a sublicense agreement to develop (177)Lu-J591 as a prostate cancer treatment. The agreement includes exclusive rights to manufacture, develop and commercialize the radiopharmaceutical worldwide, as well as a joint Phase IIb/III program. Atlab will fund certain product development and clinical trials, but no financial terms were disclosed.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST